we can gain that expertise though by working with a partner like Acadia to conduct the 1st lot of Ph III trials with NNZ 2591. Maybe we could do a Ph III trial here in Australia on a smaller scale in consultation with the TGA to expedite approval for the drug here in Australia in parallel with Acadia working with the FDA in the USA. Once we gain that expertise in house, then we could continue to conduct our own Ph III trials of 2591 in other indications. We could even possibly expand our partnerships with another pharma in Europe to expedite approval and commercialisation of 2591 there as well. We could expand globally using that partnership approach in a strategic way - just as the Chinese require partnerships between global companies wanting to manufacture in China with local Chinese companies to facilitate technology transfer. I reckon we have a broad range of options in front of us to grow organically, which I am sure Jon Pilcher is seriously investigating during this next quarter.
NEU Price at posting:
$24.98 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)